Guardant Health, Inc. shareholders approved Advisory vote on the frequency of future stockholder advisory votes regarding the compensation of the Company’s named executive officers at the 2026-06-17 meeting.
“Proposal 4 in the Proxy Statement, a proposal to determine, on an advisory (non-binding) basis, the frequency of future stockholder advisory votes regarding the compensation of the Company’s named executive officers, was determined as follows: Votes Cast for One Year Votes Cast For Two Years Votes Cast for Three Years Abstentions Broker Non-Votes 107,997,996 14,303 265,413 165,727 7,714,711”
Shareholder Votes
Guardant Health, Inc. shareholders rejected Advisory vote to approve the compensation of the Company’s named executive officers at the 2026-06-17 meeting.
“Proposal 3 in the Proxy Statement, a proposal to approve, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers, was not approved by the following vote: Votes For Votes Against Abstentions Broker Non-Votes 98,236,639 9,905,190 301,610 7,714,711”
Shareholder Votes
Guardant Health, Inc. shareholders approved Ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-17 meeting.
“Proposal 2 in the Proxy Statement, a proposal to ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, was approved by the following vote: Votes For Votes Against Abstentions 115,899,030 15,250 243,870”
Shareholder Votes
Guardant Health, Inc. shareholders approved Election of the nominees for director at the 2026-06-17 meeting.
“All of the nominees for director listed in Proposal 1 in the Company’s Definitive Proxy Statement on Schedule 14A, as filed with the Securities and Exchange Commission on April 28, 2026 (the “Proxy Statement”), were elected to serve on the Company’s board of directors by the following vote: Name of Nominee Votes For Votes Withheld Broker Non-Votes Ian Clark 70,526,891 37,916,548 7,714,711 Manuel Hidalgo Medina 81,925,123 26,518,316 7,714,711”
Earnings Releases
Guardant Health, Inc. reported the quarter ended March 31, 2026 results: revenue $301.7 million. Guidance raised.
“March 31, 2026. First Quarter 2026 Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period of 2025: • Reported total revenue of $301.7 million, an increase of 48%, driven by: ◦ Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47% ◦ Biopharma & Data revenue”
Equity Issuances
Guardant Health, Inc. issued convertible note to initial purchasers for $402.5 million aggregate principal amount.
“On November 7, 2025, the Company completed its previously announced private offering (the “Convertible Notes Offering”) of $402.5 million aggregate principal amount of 0.00% Convertible Senior Notes due 2033 (the “Notes”), which includes the exercise in full of the initial purchasers’ option to purchase up to an additional $52.5 million principal amount of Notes.”
Debt Financings
Guardant Health, Inc. incurred convertible notes of $402.5 million aggregate principal amount of 0.00% Convertible Senior Notes due 2033 with U.S. Bank Trust Company, National Association at 0.00% maturing May 15, 2033.
“On November 7, 2025, the Company completed its previously announced private offering (the “Convertible Notes Offering”) of $402.5 million aggregate principal amount of 0.00% Convertible Senior Notes due 2033 (the “Notes”), which includes the exercise in full of the initial purchasers’ option to purchase up to an additional $52.5 million principal amount of Notes.”
Debt Financings
Guardant Health, Inc. amended lease obligation of approximately $50 million with Metropolitan Life Insurance Company at annual increases of 3% to the base rent beginning in 2026 maturing December 31, 2030 or 2031, depending on the building.
“(the “Company”) entered into a third amendment to the lease (“Third Amendment”) dated November 1, 2014 between the Company and Metropolitan Life Insurance Company (the “Landlord”), as amended on October 17, 2017 and March 6, 2019 (collectively, the “Lease Agreement”), relating to the Company’s existing multibuilding facility located in Redwood City, California.”
Debt Financings
Guardant Health, Inc. incurred convertible notes of $600 million aggregate principal amount at 1.25% per annum maturing February 15, 2031.
“issued $600 million aggregate principal amount of 1.25% Convertible Senior Notes due 2031”
Roberto Mignone was appointed as Class I Director at Guardant Health, Inc..
“On October 21, 2024, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to ten and appointed Roberto Mignone., as a Class I director of the Company, to be effective as of October 21, 2024.”
Manuel Hidalgo Medina was appointed as Class II Director at Guardant Health, Inc..
“On July 17, 2024, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to nine and appointed Manuel Hidalgo Medina, M.D., Ph.D., as a Class II director of the Company, to be effective as of July 17, 2024.”
Earnings Releases
Guardant Health, Inc. reported full year 2024 results: revenue $675 to $685 million. Guidance raised.
“Guardant Health now expects full year 2024 revenue excluding screening to be in the range of $675 to $685 million, representing growth of 20% to 21% compared to full year 2023”
Earnings Releases
Guardant Health, Inc. reported the quarter ended March 31, 2024 results: revenue $168.5 million, net income $115.0 million, EPS $0.94.
“Revenue was $168.5 million for the first quarter of 2024, a 31% increase from $128.7 million for the corresponding prior year period.”
Earnings Releases
Guardant Health, Inc. updated its full year 2024 guidance (initiated).
“Expects full year 2024 revenue to be in the range of $655 to $670 million”
Earnings Releases
Guardant Health, Inc. reported the full year ended December 31, 2023 results: revenue $563.9 million. Guidance reaffirmed.
“Revenue was $563.9 million for 2023, a 25% increase from $449.5 million for the corresponding prior year period”
Earnings Releases
Guardant Health, Inc. reported the fourth quarter of 2023 results: revenue $155.1 million, net income Net loss was $187.0 million, EPS Net loss per share was $1.58.
“leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights • Revenue of $155.1 million for the fourth quarter of 2023, an increase of 22% over the fourth quarter of 2022 • Reported 46,400 tests to clinical customers and 9,500 tests to biopharmaceutical customers in”
Samir Kaul resigned as Director at Guardant Health, Inc..
“On January 26, 2024, Mr. Samir Kaul notified the board of directors (the “Board”) of Guardant Health, Inc. (the “Company”) that he intends to resign as member of the Board and as a member of the compensation committee of the Board effective February 1, 2024.”
Earnings Releases
Guardant Health, Inc. reported the three-month period ended December 31, 2023 results: revenue $153 million and $154 million.
“Fourth quarter 2023 preliminary unaudited financial results For the three-month period ended December 31, 2023, as compared to the same period of 2022: • Revenue of between $153 million and $154 million, an increase of 21%”
Earnings Releases
Guardant Health, Inc. reported the twelve-month period ended December 31, 2023 results: revenue $562 million and $563 million.
“Full year 2023 preliminary unaudited financial results For the twelve-month period ended December 31, 2023, as compared to the same period of 2022: • Revenue of between $562 million and $563 million, an increase of 25%”
Material Agreements
Guardant Health, Inc. entered into Common Stock Purchase Agreement with certain institutional investors valued at 3,387,446 shares at $26.77 per share, gross proceeds ~$90.7 million (effective 2023-12-20).
“On December 20, 2023, Guardant Health, Inc. (the “Company”) entered into a common stock purchase agreement (the “Purchase Agreement”) for the issuance and sale in a registered direct offering of 3,387,446 shares of the Company’s common stock, par value $0.00001 per share (the “Shares”), to certain institutional investors at an offering price of $26.77 per share, for gross proceeds of approximately $90.7 million.”
Earnings Releases
Guardant Health, Inc. reported the quarter ended September 30, 2023 results: revenue $143.0 million, net income $86.1 million, EPS $0.73 per share. Guidance raised.
“tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights • Revenue of $143.0 million for the third quarter of 2023, an increase of 22% over the third quarter of 2022 • Reported 43,900 tests to clinical customers and 7,500 tests to biopharmaceutical customers in”
Ines Dahne-Steuber resigned as Chief Operating Officer at Guardant Health, Inc..
“On November 2, 2023, Ms. Ines Dahne-Steuber tendered her resignation as Chief Operating Officer of Guardant Health, Inc., effective as of November 10, 2023.”
Earnings Releases
Guardant Health, Inc. reported the quarter ended June 30, 2023 results: revenue $137.2 million, net income $(0.67), EPS $(0.67). Guidance raised.
“Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance Q2 revenue increased 26% year over year driven by clinical volume growth of 49% Raises 2023 revenue guidance to $545 to $550 million PALO ALTO, Calif. August 3, 2023 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended June 30, 2023. Second Quarter 2023 Financial Highlights • Revenue of $137.2 million for the second quarter of 2023, an increase of 26% over the second quarter of 2022 • Reported 43,500 tests to clinical customers and 6,700 tests to biopharmaceutical customers in the second quarter of 2023, representing increases of 49% and 12%, respectively, over the second quarter of 2022 Recent Operating Highlights • Received new commercial plan coverage from Anthem Blue Cross and Blue Shield, Aetna,”
Shareholder Votes
Guardant Health, Inc. shareholders approved Advisory approval of named executive officer compensation at the 2023-06-14 meeting.
“Proposal 3 in the Proxy Statement, a proposal to approve, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers, was approved by the following vote: Votes For Votes Against Abstentions Broker Non-Votes 66,909,185 10,481,515 178,806 6,538,742”
Shareholder Votes
Guardant Health, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2023 at the 2023-06-14 meeting.
“Proposal 2 in the Proxy Statement, a proposal to ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, was approved by the following vote: Votes For Votes Against Abstentions 84,048,978 26,878 32,392”
Shareholder Votes
Guardant Health, Inc. shareholders approved Election of Directors at the 2023-06-14 meeting.
“All of the nominees for director listed in Proposal 1 in the Company’s Definitive Proxy Statement on Schedule 14A, as filed with the Securities and Exchange Commission on April 27, 2023 (the “ Proxy Statement ”), were elected to serve on the Company’s board of directors by the following vote: Name of Nominee Votes For Votes Withheld Broker Non-Votes Ian Clark 48,391,638 29,177,868 6,538,742 Meghan Joyce 57,913,641 19,655,865 6,538,742 Samir Kaul 76,695,081 874,425 6,538,742”
Earnings Releases
Guardant Health, Inc. reported the fiscal quarter and year ended March 31, 2023 results: revenue $128.7 million, net income Net loss was $133.5 million, EPS Net loss per share was $1.30. Guidance raised.
“tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2023. First Quarter 2023 Financial Highlights • Revenue of $128.7 million for the first quarter of 2023, an increase of 34% over the first quarter of 2022 • Reported 39,100 tests to clinical customers and 6,150 tests to biopharmaceutical customers in”
Earnings Releases
Guardant Health, Inc. reported the quarter ended March 31, 2023 results: revenue $128.7 million, net income net loss was $133.5 million, EPS Net loss per share was $1.30. Guidance raised.
“tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2023. First Quarter 2023 Financial Highlights • Revenue of $128.7 million for the first quarter of 2023, an increase of 34% over the first quarter of 2022 • Reported 39,100 tests to clinical customers and 6,150 tests to biopharmaceutical customers in”
Ines Dahne-Steuber was appointed as Chief Operations Officer at Guardant Health, Inc..
“On May 3, 2023, the Board of Directors (the “Board”) of the Guardant Health, Inc. (the “Company”) appointed Ines Dahne-Steuber to serve as the Company’s Chief Operations Officer, effective May 3, 2023.”
Auditor Changes
Guardant Health, Inc. engaged Deloitte & Touche LLP as its auditor.
“approved the engagement of Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm”
Auditor Changes
Guardant Health, Inc. dismissed Ernst & Young LLP as its auditor.
“dismissed Ernst & Young LLP (“Ernst & Young”) as the Company’s independent registered public accounting firm, each effective immediately.”
Musa Tariq was appointed as Class I director at Guardant Health, Inc..
“appointed Musa Tariq as a Class I director of the Company, to be effective as of March 6, 2023.”
Earnings Releases
Guardant Health, Inc. reported the year ended December 31, 2022 results: revenue $449.5 million, net income $654.6 million, EPS $6.41 per share.
“customers in the fourth quarter of 2022, representing an increase of 41% and 24%, respectively, over the fourth quarter of 2021. Full Year 2022 Financial Highlights • Revenue of $449.5 million for the full year 2022, an increase of 20% over the full year 2021. • Reported 124,800 tests to clinical customers and 26,000 tests to biopharmaceutical customers in the full”
Earnings Releases
Guardant Health, Inc. reported the three months ended December 31, 2022 results: revenue $126.9 million, net income $139.9 million, EPS $1.36 per share.
“data sets and advanced analytics, today reported financial results for the quarter and full year ended December 31, 2022. Fourth Quarter 2022 Financial Highlights • Revenue of $126.9 million for the fourth quarter of 2022, an increase of 17% over the fourth quarter of 2021. • Reported 36,000 tests to clinical customers and 8,200 tests to biopharmaceutical customers”
Earnings Releases
Guardant Health, Inc. reported the year ended December 31, 2022 results: revenue between $447 million and $450 million.
“Full year 2022 preliminary unaudited financial results For the twelve-month period ended December 31, 2022, as compared to the same period of 2021: • Revenue of between $447 million and $450 million”
Earnings Releases
Guardant Health, Inc. reported the quarter ended December 31, 2022 results: revenue between $124 million and $127 million.
“Fourth quarter 2022 preliminary unaudited financial results For the three-month period ended December 31, 2022, as compared to the same period of 2021: • Revenue of between $124 million and $127 million”
Earnings Releases
Guardant Health, Inc. reported the quarter ended September 30, 2022 results: revenue $117.4 million, net income $162.0 million, EPS $1.58. Guidance lowered.
“use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2022. Recent Highlights • Revenue of $117.4 million for the third quarter of 2022, an increase of 24% over the corresponding period of 2021 • Reported 32,400 tests to clinical customers and 6,750 tests to biopharmaceutical”
Steve E. Krognes was appointed as Class III director at Guardant Health, Inc..
“Effective June 30, 2022, the Board of Directors (the “ Board ”) of Guardant Health, Inc. (the “ Company ”) increased the number of directors on the Board to eight and appointed Steve E. Krognes as a Class III director of the Company.”
Bahija Jallal resigned as Director at Guardant Health, Inc..
“On May 4, 2022, Dr. Bahija Jallal notified the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) of her decision to resign as a director of the Company, effective as of the Company’s next Annual Meeting of Stockholders, which will take place on June 15, 2022.”
Stanley Meresman departed as Director at Guardant Health, Inc..
“On February 22, 2022, Stanley Meresman informed Guardant Health, Inc. (the “Company”) that he will not stand for re-election to the Company’s Board of Directors (the “Board”) when his current term expires at the Company’s next Annual Meeting of Stockholders, which will take place in June 2022.”
Myrtle Potter was appointed as Class I director at Guardant Health, Inc..
“Effective October 15, 2021, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to nine and appointed Myrtle Potter as a Class I director of the Company.”
Meghan Joyce was appointed as Class II director at Guardant Health, Inc..
“the Board increased the number of directors on the Board to eight and appointed Meghan Joyce as a Class II director”
Helmy Eltoukhy changed role as Co-Chief Executive Officer at Guardant Health, Inc..
“changed the title of Helmy Eltoukhy, the Company’s current Chief Executive Officer, to the Company’s Co-CEO”
AmirAli Talasaz resigned as Chairperson of the Board at Guardant Health, Inc..
“Dr. Talasaz announced his intent to resign from his position as Chairperson of the Board”
AmirAli Talasaz resigned as Chief Operating Officer at Guardant Health, Inc..
“Dr. Talasaz has also announced his intent to resign from his position as Chief Operating Officer of the Company”
AmirAli Talasaz was appointed as Co-Chief Executive Officer at Guardant Health, Inc..
“the Company appointed AmirAli Talasaz as the Company’s Co-CEO”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.